Stefan Müller, Evotec

Evotec’s chemoproteomic approaches to deconvolute target proteins of small molecules are unbiased, address the entire cellular proteome, and are applicable in various organisms. Target proteins are analysed by quantitative mass spectrometry, which can be based on different quantitation strategies.

Beate Kern, NanoTemper Technologies

Screening, identifying and selecting drug candidates can be some of the most complex hurdles that drug discovery scientists face in their research. The sheer throughput as well as the diverse complexity of samples versus the demands to get a precise result in a timely-manner, can be challenging. Used together, Prometheus and Dianthus systems from NanoTemper address the throughput and characterization challenges to provide precise information about protein hits from discovery to formulation steps in a screen.

Holger Erfle, Ruprecht-Karls-Universität Heidelberg

Delivery of large and functionally active biomolecules across cell membranes is a challenge, particularly for high-throughput experiments. For this purpose, we developed a novel solid-phase reverse transfection method that is suitable for the intracellular delivery of large molecules, such as proteins and antibodies, into mammalian cells with preservation of their function.

Florian Fuchs, Novartis, Basel

Three dimensional (3D) cell culture is considered clinically more relevant in mimicking the physiological environment of diseased and healthy tissues. The development of Ultra-low attachment (ULA) plates for generation and cultivation of spheroid cultures has greatly enhanced the assessment of the value of spheroidal cultures in screening.

Elena Dragicevic, Nanion Technologies

In the ever-evolving world of safety pharmacology, adequate tools and strategies are not only preferred but necessary. Ion channels have long been targets for various safety testing. However, other proteins involved in the transport of ions across membrane barriers are becoming increasingly relevant for pharmacological safety.